Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

The article mentions how symbolic recursion can destabilize identity and it’s how the true self emerges but it’s kinda vague on the details or the how and I just want to know how much of this is true?

Recursion Pharmaceuticals' market cap currently stands at just over $2 billion. The math is simple: To double, the company will need its market cap to increase to more than $4 billion. The best way to ...

Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.87% at $2.89. This change lagged the S&P 500's daily ...

Recursion Pharmaceuticals (RXRX) remains a 'Sell' as its ~$1.8B valuation is unsupported by clinical or commercial progress. REC-4881's efficacy in FAP is unremarkable versus Celebrex, with uncertain ...

What's going on with Recursion? Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since the company's management appeared on his ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...